Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- P/B of 0.11 — trading below book value
- Piotroski F-Score 5/9 — moderate financial health
- Loss-making — negative ROE of -0.8%
- Revenue declining 46% annually
BGM Group Ltd. (BGM) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $20 million . Key value metrics: P/B ratio 0.11, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
BGM Group Ltd. — Fundamental Analysis Summary
On financial health, BGM shows a moderate Piotroski F-Score of 5/9, and negative return on equity of -0.8% (sector average: -19.8%), and minimal leverage with a debt-to-equity ratio of 0.13.
StockPik's composite Value Score for BGM is 68/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
BGM reports a thin gross margin of 16.4% (sector average: 33.5%) and a negative operating margin of -2.2%.
BGM shows revenue declining at 46% year-over-year, with earnings growing at 81%.